Literature DB >> 28975469

Establishment of a bioluminescent Renca cell line for renal carcinoma research.

Jie Ding1, Chao Wang2, Xiaofeng Chang3,4.   

Abstract

PURPOSE: Luciferase modification of tumour cells enables early and non-invasive imaging to detect tumour growth in situ and could provide sensitive and effective detection of carcinoma during research and therapy.
METHODS: Renca cells, a murine renal carcinoma cell line, were infected with lentivirus expressing luciferase to obtain Renca-luc. The proliferation, invasion, and migration of Renca and Renca-luc cell lines were compared using colorimetric, Boyden chamber, and wound-healing assays. Orthotopic tumour models were established in BALB/c mice using Renca and Renca-luc cells, and tumour growth in vivo was detected using bioluminescence imaging and magnetic resonance imaging (MRI).
RESULTS: Intensity of luciferase signals from Renca-luc was positively correlated with cell number. Bioluminescence signal was detected 1 day after the establishment of the renal carcinoma model using Renca-luc and was significantly increased after 7 days. Tumour size at 7 days following the establishment of renal carcinoma models using Renca and Renca-luc was determined using MRI. The presence of renal model tumours was confirmed by histological staining. The expression of luciferase did not affect Renca cell characteristics in vitro or tumour growth in vivo.
CONCLUSION: Luciferase labelling could provide a sensitive and non-invasive evaluation method for immunological and tumour therapy of renal carcinomas.

Entities:  

Keywords:  Bioluminescence imaging (BLI); Dual-reporter; Lentivirus; Luciferase; Renca cells

Mesh:

Substances:

Year:  2017        PMID: 28975469     DOI: 10.1007/s11255-017-1707-7

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  25 in total

Review 1.  Innovations and challenges in renal cell carcinoma: summary statement from the Second Cambridge Conference.

Authors:  Michael B Atkins; Marc S Ernstoff; Robert A Figlin; Keith T Flaherty; Daniel J George; William G Kaelin; Eugene D Kwon; Towia A Libermann; W Marston Linehan; David F McDermott; Augusto C Ochoa; Allan J Pantuck; Brian I Rini; Mark A Rosen; Jeffrey A Sosman; Vikas P Sukhatme; Johannes W Vieweg; Christopher G Wood; Laura King
Journal:  Clin Cancer Res       Date:  2007-01-15       Impact factor: 12.531

2.  Anti-inflammatory activity of curcumin-loaded solid lipid nanoparticles in IL-1β transgenic mice subjected to the lipopolysaccharide-induced sepsis.

Authors:  Jiao Wang; Haoyue Wang; Rongrong Zhu; Qiang Liu; Jian Fei; Shilong Wang
Journal:  Biomaterials       Date:  2015-03-20       Impact factor: 12.479

3.  Expression of human factor IX gene in murine plasma through lentiviral vector-infected haematopoietic stem cells.

Authors:  Haoming Chen; Hengmei Yao; Lu Huang; Qi Shen; William Jia; Jinglun Xue
Journal:  Clin Exp Pharmacol Physiol       Date:  2006-12       Impact factor: 2.557

4.  Bioluminescence imaging serves as a dynamic marker for guiding and assessing thermal treatment of cancer in a preclinical model.

Authors:  Joyce T Au; Lorena Gonzalez; Chun-Hao Chen; Inna Serganova; Yuman Fong
Journal:  Ann Surg Oncol       Date:  2012-03-31       Impact factor: 5.344

5.  Cancer Statistics, 2017.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2017-01-05       Impact factor: 508.702

6.  Bioluminescence Imaging Enhances Analysis of Drug Responses in a Patient-Derived Xenograft Model of Pediatric ALL.

Authors:  Luke Jones; Jennifer Richmond; Kathryn Evans; Hernan Carol; Duohui Jing; Raushan T Kurmasheva; Catherine A Billups; Peter J Houghton; Malcolm A Smith; Richard B Lock
Journal:  Clin Cancer Res       Date:  2017-01-24       Impact factor: 12.531

7.  Cancer statistics: updated cancer burden in China.

Authors:  Wanqing Chen
Journal:  Chin J Cancer Res       Date:  2015-02       Impact factor: 5.087

8.  Cabozantinib inhibits tumor growth and metastasis of a patient-derived xenograft model of papillary renal cell carcinoma with MET mutation.

Authors:  Hongjuan Zhao; Rosalie Nolley; Andy M W Chan; Erinn B Rankin; Donna M Peehl
Journal:  Cancer Biol Ther       Date:  2016-08-11       Impact factor: 4.742

Review 9.  Kidney cancer.

Authors:  N J Vogelzang; W M Stadler
Journal:  Lancet       Date:  1998-11-21       Impact factor: 79.321

10.  Comprehensive molecular characterization of clear cell renal cell carcinoma.

Authors: 
Journal:  Nature       Date:  2013-06-23       Impact factor: 49.962

View more
  2 in total

Review 1.  Choosing The Right Animal Model for Renal Cancer Research.

Authors:  Paweł Sobczuk; Anna Brodziak; Mohammed Imran Khan; Stuti Chhabra; Michał Fiedorowicz; Marlena Wełniak-Kamińska; Kamil Synoradzki; Ewa Bartnik; Agnieszka Cudnoch-Jędrzejewska; Anna M Czarnecka
Journal:  Transl Oncol       Date:  2020-02-22       Impact factor: 4.243

2.  Demonstrating Tumor Vascular Disrupting Activity of the Small-Molecule Dihydronaphthalene Tubulin-Binding Agent OXi6196 as a Potential Therapeutic for Cancer Treatment.

Authors:  Li Liu; Regan Schuetze; Jeni L Gerberich; Ramona Lopez; Samuel O Odutola; Rajendra P Tanpure; Amanda K Charlton-Sevcik; Justin K Tidmore; Emily A-S Taylor; Payal Kapur; Hans Hammers; Mary Lynn Trawick; Kevin G Pinney; Ralph P Mason
Journal:  Cancers (Basel)       Date:  2022-08-30       Impact factor: 6.575

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.